| Biologic Therapy |
1 |
1 |
| Lung Cancer |
0 |
0.95 |
| Cancer |
0 |
0.99 |
| Renal Cell Carcinoma |
0 |
0.78 |
| Non-Small Cell Lung Cancer |
0 |
0.76 |
| Breast Cancer |
0 |
0.75 |
| Hepatocellular Carcinoma |
0 |
0.75 |
| Kidney Cancer |
0 |
0.7 |
| Gastrointestinal Cancer |
0 |
0.67 |
| Prostate Cancer |
0 |
0.65 |
| Small Cell Lung Cancer |
0 |
0.62 |
| Genomic Medicine |
0 |
0.6 |
| Tumor |
0 |
0.24 |
| Anaplastic Lymphoma Kinase |
0 |
0.19 |
| Epidermal Growth Factor Receptor |
0 |
0.13 |
| Hematology |
0 |
0.12 |
| Lung |
0 |
0.12 |
| Lymphoma |
0 |
0.12 |
| Receptors |
0 |
0.12 |
| Platelet-Derived Growth Factor |
0 |
0.08 |
| Angiogenesis Inhibitors |
0 |
0.06 |
| Breast |
0 |
0.06 |
| California |
0 |
0.06 |
| Drug Costs |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Gastrointestinal Stromal Tumor |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Humanized Monoclonal Antibody |
0 |
0.06 |
| Kidney |
0 |
0.06 |
| Leukemia |
0 |
0.06 |
| Platelet Count |
0 |
0.06 |
| Prostate |
0 |
0.06 |